A study of rezpegaldesleukin for teenagers and adults with moderate-to-severe eczema
Part of Immune system & allergy, Skin clinical trials.
This trial tests an investigational drug called rezpegaldesleukin for people aged 12 and older with moderate-to-severe atopic dermatitis (eczema) that hasn't improved enough with topical treatments. The goal is to see if it can safely reduce eczema symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 12 years or older and weigh at least 40 kg (about 88 pounds).
- You must have had eczema for at least 12 months.
- Your eczema must be moderate to severe, covering at least 10% of your body and with a certain score on skin assessments.
- You must have tried topical treatments (like steroid creams) and they didn't work well enough or you couldn't tolerate them.
- You cannot have certain other skin conditions, infections, or a history of unstable eczema.
- You cannot have taken certain other eczema treatments like biologic drugs or JAK inhibitors before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental medicine (rezpegaldesleukin) for people with moderate to severe eczema. It aims to see if the drug can calm the immune system and improve skin symptoms when other treatments haven't worked.
This trial tests an injectable drug called lebrikizumab for people with moderate-to-severe eczema (atopic dermatitis) that has not been well controlled with topical treatments. It may help reduce skin symptoms and itching.
This trial tests a study drug (PF-08049820) for people with moderate to severe eczema who haven't found a suitable prescription treatment. It aims to see if the drug can improve skin symptoms and itching.
This trial tests an investigational drug called BxC-I17e, given as an injection under the skin, for people with moderate to severe atopic dermatitis (eczema) that hasn't improved enough with standard creams. The goal is to see if it is safe and works well.
This trial tests a new injectable drug called SKB575 for people with moderate to severe atopic dermatitis (eczema). It aims to see how safe and effective the drug is, especially for those who haven't had success with strong creams or pills.
This trial tests a new stem cell injection called ADSTEM for people with moderate to severe eczema that hasn't improved with standard treatments. The goal is to see if it can reduce eczema symptoms like itching, redness, and skin rash.
Hear when a new Moderate to Severe Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.